Concepedia

Ho-June Lee

HL

5

Publications

883

Citations

5

H-Index

2014

Active since

Affiliations

PDL BioPharma (United States)(Current)

Discovery Centre

Gene Therapy Laboratory

Translational Research in Oncology

Ho-June Lee is an author at PDL BioPharma (United States) specializing in cell signaling, cell biology, and cancer research.

ORCID

Top concepts

Publications per year

2014–2023

5

Publications

5

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Ho-June Lee, Guanglei Zhuang, Yi Cao et al. · Cancer Cell · 2014 · 548 citations · Full text

, , +9

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Thijs J. Hagenbeek, Marc Hafner, Rana Mroue et al. · Nature Cancer · 2023 · 169 citations · Full text

The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors

Thijs J. Hagenbeek, Joshua D. Webster, Noelyn M. Kljavin et al. · Science Signaling · 2018 · 87 citations

Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways

Trang H. Pham, Thijs J. Hagenbeek, Ho-June Lee et al. · Cancer Discovery · 2020 · 54 citations · Full text

Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells

Ho-June Lee, Yi Cao, Victoria C. Pham et al. · Molecular Cancer Therapeutics · 2017 · 25 citations

Rows per page

1–5 of 5